Making Integrated Care Work

Contact Us: 202.684.7457

SAMHSA-HRSA Center for Integrated Health Solutions

View Menu
Glossary
Facebook Twitter Listserve Ask a Question Email

Event

« Back to Calendar of Events

Conference Details

Register to Discuss Increasing the Use of Naloxone to Reduce the Incidence of Opioid Drug Overdose Fatalities

Start Date: June 21, 2015
End Date: June 21, 2015
Location:
Event Details:

Registration: If you wish to attend the public meeting or provide testimony during the open public hearing, please email your registration to NaloxoneWorkshop@fda.hhs.gov by June 22, 2015. 

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research, in collaboration with the National Institutes on Drug Abuse, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, will hold a public meeting to discuss increasing the use of naloxone to reduce the incidence of opioid drug overdose fatalities. During the meeting, academic and government experts, industry representatives, and patient advocates will discuss which populations are at-risk for opioid drug overdose and how we can work together to encourage the use of naloxone to reduce the risk of overdose from opioid drugs.

Date and Time: The public meeting will be held on July 1, 2015, from 8 a.m. to 5 p.m. and on July 2, 2015, from 8 a.m. to 3 p.m. The open public hearing will be held between 1 p.m. and 2 p.m. on July 1, 2015, and between 1 p.m. and 2 p.m. on July 2, 2015, during which speaker testimony will be accepted.

Location: For those wishing to attend in person, the public meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-0002.

Webcast information will be posted a few days prior to the meeting – please check the meeting webpage for updates. 

For more information see the Federal Register Notice:https://www.federalregister.gov/articles/2015/05/19/2015-12061/exploring-naloxone-uptake-and-use-public-meeting-request-for-comments

The SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) does not endorse or attest to the quality of the content. Questions regarding content, recordings, and additional information should be directed to the host organization and/or presenter.

Contact Email: NaloxoneWorkshop@fda.hhs.gov
Description:
More Info Url:
Registration Url: NaloxoneWorkshop@fda.hhs.gov

Call Our Helpline: 202-268-7457

« Back to Calendar of Events

Conference Details

Register to Discuss Increasing the Use of Naloxone to Reduce the Incidence of Opioid Drug Overdose Fatalities

Start Date: June 21, 2015
End Date: June 21, 2015
Location:
Event Details:

Registration: If you wish to attend the public meeting or provide testimony during the open public hearing, please email your registration to NaloxoneWorkshop@fda.hhs.gov by June 22, 2015. 

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research, in collaboration with the National Institutes on Drug Abuse, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, will hold a public meeting to discuss increasing the use of naloxone to reduce the incidence of opioid drug overdose fatalities. During the meeting, academic and government experts, industry representatives, and patient advocates will discuss which populations are at-risk for opioid drug overdose and how we can work together to encourage the use of naloxone to reduce the risk of overdose from opioid drugs.

Date and Time: The public meeting will be held on July 1, 2015, from 8 a.m. to 5 p.m. and on July 2, 2015, from 8 a.m. to 3 p.m. The open public hearing will be held between 1 p.m. and 2 p.m. on July 1, 2015, and between 1 p.m. and 2 p.m. on July 2, 2015, during which speaker testimony will be accepted.

Location: For those wishing to attend in person, the public meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-0002.

Webcast information will be posted a few days prior to the meeting – please check the meeting webpage for updates. 

For more information see the Federal Register Notice:https://www.federalregister.gov/articles/2015/05/19/2015-12061/exploring-naloxone-uptake-and-use-public-meeting-request-for-comments

The SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) does not endorse or attest to the quality of the content. Questions regarding content, recordings, and additional information should be directed to the host organization and/or presenter.

Contact Email: NaloxoneWorkshop@fda.hhs.gov
Description:
More Info Url:
Registration Url: NaloxoneWorkshop@fda.hhs.gov

© 2011 NCBH, all rights reserved.
1400 K Street NW | Suite 400
Washington, D.C. 20005

Email: integration@thenationalcouncil.org

Phone: 202-684-7457